Riudavets Mariona, Birsen Gary, Slomka Jeremy, Alitano Marco, Damotte Diane, Wislez Marie
Service de Pneumologie et Oncologie thoracique, Hôpital Cochin, Assistance publique-Hôpitaux de Paris, Institut du Cancer Paris CARPEM, Paris, France.
Service de Chirurgie thoracique, Hôpital Cochin, Assistance publique-Hôpitaux de Paris, Paris, France.
Bull Cancer. 2025 Mar;112(3S1):3S39-3S45. doi: 10.1016/S0007-4551(25)00156-0.
For decades, early-stage, resecable, although potentially curable, non-small cell lung cancer (NSCLC) has been marred by unacceptably high recurrence rates. Anti-PD(L)1 immune checkpoint inhibitors have revolutionized the treatment of advanced NSCLC; the recent approvals of these drugs in the perioperative setting will now transform the paradigm therapeutics of localized NSCLC. In this review, we focus on the role of perioperatively administered immune checkpoint inhibitors in resectable NSCLC, synthesizing the results of early clinical trials, and discussing future directions.
几十年来，早期、可切除的非小细胞肺癌（NSCLC）虽然有可能治愈，但复发率高得令人难以接受，一直备受困扰。抗程序性死亡受体 1（PD-1）/程序性死亡配体 1（PD-L1）免疫检查点抑制剂彻底改变了晚期 NSCLC 的治疗方式；这些药物最近在围手术期的获批，将改变局限性 NSCLC 的治疗模式。在这篇综述中，我们重点关注围手术期应用免疫检查点抑制剂在可切除 NSCLC 中的作用，综合早期临床试验结果，并探讨未来的发展方向。
